Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Feb 12, 2015 (12 years ago)

Bromfenac Ophthalmic Solution 0.09%

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

CGMP Deviations: Product excipient was not re-tested at the appropriate date.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Bromfenac Ophthalmic Solution 0.09%, Rx Only. Mfg For: Apotex Corp., Weston, FL, 33326. Available in a) 1.7 mL Bottle, NDC: 60505-0595-5; b) 2 x 1.7 mL Bottles, NDC: 60505-0595-6; c) 2.5 mL Bottles, NDC: 60505-0596-4.

Affected NDCs 60505-0595-05 60505-0595-06 60505-0596-04

Compare with the code on your package — it is the most precise check available.

Drug: Bromfenac Category: Eye Drops & Ophthalmic

Recalling firm
Apotex Inc.
Origin
N/A, Canada
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0487-2015 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Bromfenac recalls

See all
Class II · Moderate risk

Bromfenac Ophthalmic Solution 0.07%

Failed Impurities/Degradation Specifications: out of specification at the time of testing i.e. 20th month stability testing.

Ongoing Impurity / degradation Alembic Pharmaceuticals, INC. NDC 62332-583-03 Recall number pending

Other recalls by Apotex Inc.

All 2015 recalls
Class II · Moderate risk

Paxil CR

Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria

Ongoing Dissolution failure Apotex Corp. NDC 60505-4379-3 D-0804-2026
Class II · Moderate risk

Desmopressin Nasal Spray

Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.

Ongoing Packaging defect Apotex Corp. NDC 60505-0815-0 D-0510-2026